Short- and Longer-Term Healthcare Resource Utilization and Related Costs With Psoriasis in Brazilian Private Market
Author(s)
Joao Paulo Dos Reis Neto, PhD, MD1, JULIANA BUSCH, MD2.
1ceo, Diretor-Presidente da Capesesp, Rio de Janeiro, Brazil, 2CAPESESP, Rio de Janeiro, Brazil.
1ceo, Diretor-Presidente da Capesesp, Rio de Janeiro, Brazil, 2CAPESESP, Rio de Janeiro, Brazil.
OBJECTIVES: The global psoriasis prevalence rate is around 2 to 3% of the world population with a substantial economic burden. This study analyzes healthcare resource utilization (HCRU) and costs in patients with psoriasis and use of immunobiological (IMB).
METHODS: Retrospective study of patients identified with psoriasis (ICD-10 code L40-L409) between Jan/2019 and Dez/2024 in a nationwide base of health insurance claims data of 60,824 beneficiaries. Available data include demographics, comorbidities, healthcare resource utilization (HCRU), and costs, including visits, surgery, emergency department, therapies and tests. The main results of the group of patients using imunobiologics were compared with other patients who did not use this medication. Chi-square and Fisher’s exact and Student’s t tests for categorical/continuous measures. Statistical significance for p<0.05.
RESULTS: In our analysis, the age-standardized prevalence rate of psoriasis is 74 cases per 100,000 population (61,5 years; 52% female). The rate of procedures per year for visits, emergency room, tests, therapies, and hospitalization were 6.09, 0.54, 52.25, 5.08 and 0.23, respectively. Annualized healthcare costs in 12 months were US$10,882 per/patient (83.3% IMB). Most reimbursed biological drugs were infliximab (41.3%), secukinumab (29.7%), ixekizumab (18.4%) and others (10.6%). When comparing patients who used IMB with those who did not use IMB, we found a lower annual hospitalization rate (0.21 and 0.24) and a shorter average hospitalization time (1.6 and 8.3 days) (p<0.05).
CONCLUSIONS: This study analyzed the healthcare costs associated with patients diagnosed with psoriasis, highlighting a substantial economic burden that escalates as the disease progresses. Over the past decade, the therapeutic landscape for psoriasis has undergone a significant transformation with the advent of biologic therapies. The benefits are well known, but they come at a very high cost. Therefore, it is imperative for healthcare managers to develop strategies that enhance access to these innovative therapies, aiming to improve patients’ quality of life.
METHODS: Retrospective study of patients identified with psoriasis (ICD-10 code L40-L409) between Jan/2019 and Dez/2024 in a nationwide base of health insurance claims data of 60,824 beneficiaries. Available data include demographics, comorbidities, healthcare resource utilization (HCRU), and costs, including visits, surgery, emergency department, therapies and tests. The main results of the group of patients using imunobiologics were compared with other patients who did not use this medication. Chi-square and Fisher’s exact and Student’s t tests for categorical/continuous measures. Statistical significance for p<0.05.
RESULTS: In our analysis, the age-standardized prevalence rate of psoriasis is 74 cases per 100,000 population (61,5 years; 52% female). The rate of procedures per year for visits, emergency room, tests, therapies, and hospitalization were 6.09, 0.54, 52.25, 5.08 and 0.23, respectively. Annualized healthcare costs in 12 months were US$10,882 per/patient (83.3% IMB). Most reimbursed biological drugs were infliximab (41.3%), secukinumab (29.7%), ixekizumab (18.4%) and others (10.6%). When comparing patients who used IMB with those who did not use IMB, we found a lower annual hospitalization rate (0.21 and 0.24) and a shorter average hospitalization time (1.6 and 8.3 days) (p<0.05).
CONCLUSIONS: This study analyzed the healthcare costs associated with patients diagnosed with psoriasis, highlighting a substantial economic burden that escalates as the disease progresses. Over the past decade, the therapeutic landscape for psoriasis has undergone a significant transformation with the advent of biologic therapies. The benefits are well known, but they come at a very high cost. Therefore, it is imperative for healthcare managers to develop strategies that enhance access to these innovative therapies, aiming to improve patients’ quality of life.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
RWD173
Topic
Epidemiology & Public Health, Health Service Delivery & Process of Care, Real World Data & Information Systems
Topic Subcategory
Health & Insurance Records Systems
Disease
Sensory System Disorders (Ear, Eye, Dental, Skin), Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)